Report on member-distributor performance metrics for 2019
New data released by the Healthcare Distribution Alliance (HDA) Research Foundation points to the supply chain efficiencies generated by HDA-member specialty drug distributors. According to the latest edition of Specialty Pharmaceutical Distribution: Facts, Figures and Trends, specialty distributors serve as an important link between 176 manufacturers and more than 49,000 provider ship-to points for administration or dispensing to patients. In citing data from IQVIA, HDA noted that the specialty pharma market reached $426 billion in 2019.
Independent physician-owned and -operated clinics make up the biggest customer segment (about 18,000), followed by hospitals, retail pharmacies and specialty pharmacies. As in years past, oncology products accounted for the highest shipping volume, at 52% of specialty distributors’ weighted average sales, followed by products in the inflammatory/autoimmune, supportive care, ophthalmology and hemophilia/bleeding disorder groups.
The primary data are gathered through a survey of HDA specialty distributors who have recorded yearly sales greater than $1 billion for the 2019 fiscal year; they also have combined average gross specialty sales of $23 billion. The Covid-19 response is not reflected in this particular publication.
Among the 2019 highlights:
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
Is Compounding the Answer to the Semaglutide Shortage? Experts Weigh In
October 30th 2024In this Q&A, Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss the challenges faced by patients and healthcare providers due to drug shortages, particularly for semaglutide and other medications.